Beam Therapeutics Inc
Q1 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +7.22%.
Did BEAM Beat Earnings? Q1 2025 Results
Beam Therapeutics delivered a disappointing first quarter for fiscal 2025, missing on both the top and bottom lines as heavy clinical investment weighed on results. The company reported a loss of $1.24 per share, coming in 5.86% below the consensus estimate of $1.17, while revenue of $7.47 million fell sharply short of the $14.68 million analysts had anticipated, a 49.13% miss despite being essentially flat year over year, up just 0.8% from $7.41 million in Q1 2024. The primary driver of the widening net loss, which reached $109.27 million compared to $98.67 million a year earlier, was a surge in R&D spending to $98.82 million as Beam advanced multiple programs simultaneously. The quarter's most consequential development was positive initial clinical data for BEAM-302 in alpha-1 antitrypsin deficiency, which supported a $500.00 million oversubscribed financing that lifted cash to $1.22 billion, a runway management says extends into 2028 and covers key milestones including updated BEAM-302 data expected at a medical conference in the second half of 2025.
- Advancement of multiple clinical-stage programs driving increased R&D investment
- License and collaboration revenue remained stable year-over-year
- $500 million oversubscribed registered direct financing strengthened balance sheet
“Beam has had a tremendous start to what we anticipate will be a transformative year. In March, we achieved a historic milestone with BEAM-302, delivering the first-ever clinical genetic correction of a disease-causing mutation for alpha-1 antitrypsin deficiency. Building on this momentum, we have swiftly advanced the program—initiating the fourth cohort of Part A of the Phase 1/2 BEAM-302 study and securing U.S. FDA clearance for our investigational new drug application, positioning us for continued rapid progress.”
Beam Therapeutics CEO, on the earnings call
Forward Guidance & Outlook
Beam expects its cash, cash equivalents and marketable securities of $1.2 billion as of March 31, 2025, including net proceeds from the recent $500 million financing, to fund anticipated operating expenses and capital expenditure requirements into 2028. Key milestones include: continued dose escalation in Part A of the BEAM-302 Phase 1/2 trial with further data expected at a medical conference in H2 2025; dosing the first patient in Part B of the BEAM-302 trial (including AATD patients with mild to moderate liver disease) in H2 2025; continued dosing in the Phase 1/2 trial of BEAM-301 for GSDIa; dosing 30 patients in the BEACON Phase 1/2 trial of BEAM-101 in SCD by mid-2025; presentation of updated BEACON data at EHA 2025 in June; and initiation of a Phase 1 healthy volunteer trial of BEAM-103 (ESCAPE monoclonal antibody) by year-end 2025.
BEAM YoY Financials
Figures from SEC filings and company reports. Not investment advice.